“Market close, VIVE reported slightly better-than-expected 3Q18 revenue, but a wider GAAP loss per share. The company lowered its 2018 revenue guidance to $17.5M-$18.5M, from $22M-$24M, primarily due to industry-wide headwinds. VIVE has three ongoing or planned pivotal clinical trials and one ongoing feasibility study to evaluate its Viveve System for indications including improved sexual function and stress urinary incontinence (SUI). We are introducing quarterly 2019 estimates, and lowering our go-forward revenue estimates.”
According to TipRanks.com, Vendetti is a 5-star analyst with an average return of 11.5% and a 55.9% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Ellex Medical Lasers Limited, Restoration Robotics Inc, and Ra Medical Systems Inc.
Viveve Medical Inc has an analyst consensus of Strong Buy, with a price target consensus of $6.50.
Based on Viveve Medical Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $11.52 million. In comparison, last year the company had a GAAP net loss of $9.62 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Viveve Medical, Inc. engages in the provision of health products. Its activities include development and distribution of women’s health solutions. Its products include non-surgical, non-ablative medical device that remodels collagen and restores vaginal tissue. The company was founded on March 3, 1987 and is headquartered Englewood, CO.